Changes in Hong Kong stocks | Kangfang Biotech (09926) rose more than 8% in early trading, Evosi's biliary tract cancer phase III study successfully beat Duvaliu head-to-head

The Zhitong Finance App learned that Kang Fang Biotech (09926) rose more than 8% in early trading. As of press release, it had risen 7.76% to HK$95.8, with a turnover of HK$413 million.

According to the news, Kang Fang Biotech announced that it achieved overall survival (OS), the main research endpoint of the world's first PD-1/VEGF bispecific immunotherapy drug evossi (idafang®), and the contrast Valliou (PD-L1) combination chemotherapy plan. In a randomized, controlled, double-blind, multicenter phase III clinical study (AK112-309/Harmoni-GI1) for first-line treatment of advanced biliary tract cancer, it achieved positive results with significant statistical and clinical benefits.

According to the announcement, the study also reached all key secondary endpoints such as PFS and ORR, and the baseline characteristics of the subjects were balanced. It was the first phase III study in the field of biliary tract cancer to obtain significant positive OS results using the world's best gold standard (PD-L1 monoclonal antibody combined chemotherapy). It is a major milestone in the treatment of biliary tract cancer. This breakthrough marks that after receiving 4 phase III positive results in lung cancer, Evosi has once again obtained important positive phase III clinical results in other solid tumor treatment fields.